Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

Enrolling by Invitation

PHASE4All AgesInterventionalTreatment

Allievex Corporation

~15 participants

Updated 2023-08-09 on ClinicalTrials.gov

What's tested:AX 250

At a glance

Recruiting sites

0 of 6 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Primary - neurocognition

Measured over baseline to 144 weeks of treatment

MPS III B

NCT05492799

This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Fundación Cardio Infantil - Instituto de Cardiología
Bogotá, Colombiano site contact published
Gazi University Faculty of Medicine
Ankara, Turkey (Türkiye)no site contact published
Great Ormond Street Hospital For Children, NHS Foundation Trust
London, United Kingdomno site contact published
UCSF Benioff Children's Hospital Oakland
Oakland, Californiano site contact published
University Medical Center Hamburg-Eppendorf
Hamburg, Germanyno site contact published
UPMC Children's Hospital Pittburgh
Pittsburgh, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

This trial hasn't published a contact. View it on ClinicalTrials.gov

Primary - neurocognitionbaseline to 144 weeks of treatment
the rate of change in score from neurocognitive assessment using validated scale